Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy.

Abstract

Abnormal fibrogenic repair response upon alveolar injury is believed to play an important role in the pathogenesis of idiopathic pulmonary fibrosis (IPF). PRM-151 (recombinant human pentraxin-2, also known as serum amyloid P), has been shown to reduce fibrosis in preclinical lung fibrosis models, and was well tolerated with a favourable pharmacokinetic profile in an earlier single-dose phase I study.A randomised, double-blind, placebo-controlled, multiple ascending dose trial was performed to assess the tolerability and pharmacokinetic and pharmacodynamic characteristics of multiple doses of PRM-151 in IPF patients. Subjects in three successive cohorts (1, 5, or 10 mg·kg(-1) versus placebo) received intravenous study drug on days 1, 3, 5, 8 and 15, and were followed-up to day 57.PRM-151 was well tolerated at all dose levels, with no serious adverse reactions. Administration of PRM-151 resulted in two- to eight-fold dose-dependent increases in circulating pentraxin-2 levels. Forced vital capacity and 6-min walk test showed trends towards improvement in the combined PRM-151 dose groups. On high-resolution computed tomography scans, stable or improved lung volume unoccupied by interstitial lung abnormality was noted in some PRM-151 subjects compared to placebo subjects on day 57.The efficacy of PRM-151 in IPF remains to be investigated in dedicated future trials.

• Authors: Bernt van den Blink, Marlous R Dillingh, Leo C Ginns, Lake D Morrison, Matthijs Moerland, Marlies Wijsenbeek, Elizabeth G Trehu, Brian J Bartholmai, Jacobus Burggraaf
• Journal: The European respiratory journal (Eur Respir J) Vol. 47 Issue 3 Pg. 889-97 (Mar 2016) ISSN: 1399-3003 [Electronic] England
• PMID: 26869678 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright ©ERS 2016.

Chemical References

• Homeodomain Proteins
• PRM-151
• Recombinant Proteins
• Serum Amyloid P-Component

Topics

• Adult
• Aged
• Aged, 80 and over
• Dose-Response Relationship, Drug
• Double-Blind Method
• Exercise Test
• Female
• Homeodomain Proteins (adverse effects, pharmacokinetics)
• Humans
• Idiopathic Pulmonary Fibrosis (drug therapy)
• Lung (physiopathology)
• Male
• Middle Aged
• Netherlands
• Recombinant Proteins (adverse effects, pharmacokinetics)
• Respiratory Function Tests
• Serum Amyloid P-Component (adverse effects, pharmacokinetics)
• Treatment Outcome
• United States